Mafenide

Summary

Mafenide (CHEMBL419) is an approved small molecule (ATC D06BA03); indicated across 1 condition including osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D06BA03
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 186.23 Da · C7H10N2O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL419
Name	Mafenide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3998
ATC	D06BA03
Molecular formula	C7H10N2O2S
Molecular weight	186.23
InChIKey	TYMRLRRVMHJFTF-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1CN)S(=O)(=O)N

IUPAC name: 4-(aminomethyl)benzenesulfonamide

Also known as: D06BA03, Mafenida, Mafenide, NSC-34632, Sulfamylon, SID11112297, MAFENIDE, C0088644, mafenide

Parent form; salt/anhydrous children: CHEMBL1201161, CHEMBL1593568

Patent coverage: 3,885 distinct patent families (14,690 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 19 (assay-derived). Sample: Carbonic anhydrase 2, Carbonic anhydrase 13, Carbonic anhydrase 7, Carbonic anhydrase 1, Carbonic anhydrase 4, Carbonic anhydrase 6, Carbonic anhydrase 12, Carbonic anhydrase 14, Carbonic anhydrase 9, Carbonic anhydrase 4.

Bioactivity

ChEMBL activities: 93 potent at pChembl ≥ 5 of 144 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CA12	9.52	Ki	0.3	nM	CHEMBL_ACT_1424858
CA12	9.52	Ki	0.3	nM	CHEMBL_ACT_1436070
CA12	9.52	Ki	0.3	nM	CHEMBL_ACT_3256598
CA12	9.52	Ki	0.3	nM	CHEMBL_ACT_8057354
Q9D6N1	7.39	Ki	41	nM	CHEMBL_ACT_1423346
Q9D6N1	7.39	Ki	41	nM	CHEMBL_ACT_68088
CA7	7.12	Ki	75	nM	CHEMBL_ACT_1423345
CA9	6.99	Ki	103	nM	CHEMBL_ACT_1424857
CA9	6.99	Ki	103	nM	CHEMBL_ACT_1455362
CA9	6.99	Ki	103	nM	CHEMBL_ACT_1519908
CA9	6.99	Ki	103	nM	CHEMBL_ACT_1804125
CA9	6.99	Ki	103	nM	CHEMBL_ACT_2495913
CA9	6.99	Ki	103	nM	CHEMBL_ACT_3256814
CA9	6.99	Ki	103	nM	CHEMBL_ACT_595211
CA9	6.99	Ki	103	nM	CHEMBL_ACT_68087
CA9	6.99	Ki	103	nM	CHEMBL_ACT_8057317
CA9	6.99	Ki	103	nM	CHEMBL_ACT_93987
CA2	6.77	Ki	170	nM	CHEMBL_ACT_1040890
CA2	6.77	Ki	170	nM	CHEMBL_ACT_10946371
CA2	6.77	Ki	170	nM	CHEMBL_ACT_1096808
CA2	6.77	Ki	170	nM	CHEMBL_ACT_1246786
CA2	6.77	Ki	170	nM	CHEMBL_ACT_1258398
CA2	6.77	Ki	170	nM	CHEMBL_ACT_12656006
CA2	6.77	Ki	170	nM	CHEMBL_ACT_13286772
CA2	6.77	Ki	170	nM	CHEMBL_ACT_13866422
CA2	6.77	Ki	170	nM	CHEMBL_ACT_1423344
CA2	6.77	Ki	170	nM	CHEMBL_ACT_1436069
CA2	6.77	Ki	170	nM	CHEMBL_ACT_1437904
CA2	6.77	Ki	170	nM	CHEMBL_ACT_1455361
CA2	6.77	Ki	170	nM	CHEMBL_ACT_14661434

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00675922	PHASE2/PHASE3	TERMINATED	Study of the Treatment of Burn Wounds With Antimicrobial Topical Soaks

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol,	CPIC	G6PD

PharmGKB also curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).